Intensive Insulin Glulisine Therapy in Patients With Type 2 Diabetes Inadequately Controlled With Basal Insulin and Oral Glucose-lowering Drugs
A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 207 participants.
Also called NCT01203111
- Study
- In this atlas
Overview
- Design
- Interventional study; non-randomized; no masking; primary purpose treatment
- Phase
- Phase 4
- Enrolled
- 207 participants
- Sponsor
- Registry
-
NCT01203111
-
- Start date
- (registry gives no type)
- Primary completion
- (actual)
- Completion
- (actual)
- Countries
- Algeria, Brazil, Israel, Lebanon, Mexico, Morocco, Peru, Saudi Arabia, United Arab Emirates, Venezuela
- Registry status
- Completed
Technical summary
Registry record NCT01203111. Non-randomized; no masking; primary purpose treatment. Start 2010-12 (registry gives no type); primary completion 2012-07 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Intensive Insulin Glulisine Therapy in Patients With Type 2 Diabetes Inadequately Controlled With Basal Insulin and Oral Glucose-lowering Drugs
- Acronym
- CHANGING
- Condition
- Diabetes Mellitus, Type 2
- Intervention (Drug)
- INSULIN GLARGINE
- Intervention (Drug)
- INSULIN GLULISINE
- Lead sponsor
- Sanofi
Record details
- Record id
cardio:ct-nct01203111- Content hash
04b58745cfef65de4718dad1447c1dbde3c1c46b3fd4fd7721f9311145da878c